Type 2 Diabetes: Pipeline Review, H1 2018 - ResearchAndMarkets.com

DUBLIN--()--The "Type 2 Diabetes - Pipeline Review, H1 2018" report has been added to ResearchAndMarkets.com's offering.

This latest pipeline guide provides comprehensive information on the therapeutics under development for Type 2 Diabetes (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Type 2 Diabetes (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Type2 diabetes and features dormant and discontinued projects.

The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 10, 2, 29, 63, 72, 6, 220, 65 and 12 respectively. Similarly, the Universities portfolio in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 1, 1, 1, 62 and 18 molecules, respectively.

Key Topics Covered

  1. Introduction
  2. Type 2 diabetes - Overview
  3. Type 2 diabetes - Therapeutics Development
  4. Type 2 diabetes - Therapeutics Assessment
  5. Type 2 diabetes - Companies Involved in Therapeutics Development
  6. Type 2 diabetes - Drug Profiles
  7. Type 2 diabetes - Dormant Projects
  8. Type 2 diabetes - Discontinued Products
  9. Type 2 diabetes - Product Development Milestones
  10. Appendix

Companies Mentioned

  • Amgen Inc
  • Aphios Corp
  • Arecor Ltd
  • Arena Pharmaceuticals Inc
  • AstraZeneca Plc
  • AusBio Ltd
  • Avadel Pharmaceuticals Plc
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Boston Therapeutics Inc
  • Bristol-Myers Squibb Co
  • C4X Discovery Holdings PLC
  • Cadila Healthcare Ltd
  • Daewoong Pharmaceutical Co Ltd
  • Eli Lilly and Co
  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences Inc
  • GlaxoSmithKline Plc
  • Hyundai Pharmaceutical Co Ltd
  • JHL Biotech Inc
  • Johnson & Johnson
  • Kissei Pharmaceutical Co Ltd
  • LG Chem Ltd
  • MedImmune LLC
  • Merck & Co Inc
  • Mitsubishi Chemical Holdings Corp
  • Novartis AG
  • Novo Nordisk AS
  • Pfizer Inc
  • Renova Therapeutics Inc
  • Sanofi
  • SK Chemicals Co Ltd
  • Takeda Pharmaceutical Co Ltd
  • Teijin Pharma Ltd
  • Toray Industries Inc

For more information about this report visit https://www.researchandmarkets.com/research/qr59lz/type_2_diabetes?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Endocrine and Metabolic Disorders Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Endocrine and Metabolic Disorders Drugs